Q3 2016 13F Holders as of 30 Sep 2016
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Market price (% of par)
-
112.01%
-
Total 13F principal
-
$407,063,000
-
Principal change
-
+$397,063,000
-
Total reported market value
-
$456,083,000
-
Number of holders
-
43
-
Value change
-
+$444,891,318
-
Number of buys
-
42
-
Number of sells
-
1
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q3 2016
As of 30 Sep 2016,
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 was held by
43 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$407,063,000
in principal (par value) of the bond.
The largest 10 bondholders included
CITADEL ADVISORS LLC, WOLVERINE ASSET MANAGEMENT LLC, UBS ASSET MANAGEMENT AMERICAS INC, Allianz Asset Management GmbH, LINDEN ADVISORS LP, HIGHFIELDS CAPITAL MANAGEMENT LP, Capital World Investors, OAKTREE CAPITAL MANAGEMENT LP, MACKAY SHIELDS LLC, and LAZARD ASSET MANAGEMENT LLC.
This page lists
43
institutional bondholders reporting positions
for the Q3 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.